MB
ZNTL icon

MPM BioImpact’s Zentalis Pharmaceuticals ZNTL Stock Holding History

MPM BioImpact’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,106,851
Closed -$3.35M – 53
2024
Q4 		$3.35M Sell
1,106,851
-358,950
-24% -$1.18M 0.48% 43
2024
Q3 		$5.39M Buy
1,465,801
+15,801
+1% +$57.4K 0.81% 33
2024
Q2 		$5.93M Sell
1,450,000
-66,183
-4% -$739K 0.92% 35
2024
Q1 		$23.9M Buy
+1,516,183
New +$20.9M 3.84% 4

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM BioImpact's ZNTL Position: Q1 2025 in Review

MPM BioImpact sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 1,106,851 shares — an estimated $3.35M sold.

MPM BioImpact first reported a position in ZNTL in Q1 2024 and held it in 4 quarters. The position peaked at $23.9M in Q1 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • MPM BioImpact reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 1,106,851 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $3.35M.
  • MPM BioImpact first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • MPM BioImpact's Zentalis Pharmaceuticals position peaked at $23.9M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.